ADMA

ADMA Biologics, Inc. NASDAQ

Healthcare ·Biotechnology ·US · admabiologics.com

$10.31

Mkt Cap $2.4B

52w Low $7.21 18.3% of range 52w High $24.17

50d MA $12.53 200d MA $15.83

P/E (TTM) 17.0x

EV/EBITDA 21.9x

P/B 5.2x

Debt/Equity 0.2x

ROE 30.8%

P/FCF 156.2x

RSI (14) —

ATR (14) —

Beta 0.82

50d MA $12.53

200d MA $15.83

Avg Volume 5.8M

About

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG pro…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 25, 2026	AMC	0.18	0.20	+8.1%	15.68	+3.6%	-3.2%	-0.7%	+5.7%	+4.5%	+5.5%	—
Nov 5, 2025	AMC	0.16	0.16	+0.0%	15.37	-3.1%	-8.7%	-5.5%	-4.3%	+4.3%	+7.1%	—
Aug 6, 2025	AMC	0.14	0.15	+7.1%	18.54	-14.5%	-9.7%	-10.9%	-11.7%	-9.6%	-7.2%	—
May 7, 2025	AMC	0.16	0.14	-12.5%	23.61	-3.7%	-10.2%	-15.4%	-13.4%	-15.8%	-17.5%	—
Mar 3, 2025	AMC	0.15	0.14	-6.7%	15.83	-5.9%	+7.5%	+11.7%	+6.8%	+7.5%	+4.9%	—
Nov 7, 2024	AMC	0.13	0.15	+15.4%	19.72	+5.3%	+14.7%	+14.0%	+10.4%	+8.9%	+2.4%	—
Aug 8, 2024	AMC	0.08	0.13	+62.5%	12.19	+23.9%	+30.9%	+34.9%	+41.7%	+44.1%	+44.3%	—
May 9, 2024	AMC	0.06	0.08	+33.3%	6.93	+18.3%	+27.1%	+26.8%	+32.2%	+31.3%	+30.7%	—
Feb 28, 2024	AMC	-0.01	0.04	+420.0%	5.38	+0.0%	-0.4%	+2.6%	+6.3%	+7.8%	+13.8%	—
Nov 8, 2023	AMC	0.00	0.01	+233.3%	3.62	+10.5%	+5.8%	+4.1%	+3.3%	+6.9%	+5.0%	—
Aug 9, 2023	AMC	-0.02	-0.02	-19.8%	4.06	+3.4%	+6.2%	+10.3%	+13.5%	+11.8%	+9.4%	—
May 10, 2023	AMC	-0.05	-0.03	+40.0%	3.57	+9.2%	+10.9%	+18.2%	+17.4%	+14.3%	+15.1%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 21	Canaccord Genuity	Initiates	Buy	$21	$10.88	$11.12	+2.2%	-0.9%	+0.6%	+1.8%	+3.5%	+0.5%
Apr 13	Mizuho	Maintains	Outperform → Outperform	—	$9.70	$9.74	+0.4%	+7.0%	+8.1%	+9.8%	+10.7%	+13.5%
Mar 26	Cantor Fitzgerald	Downgrade	Overweight → Neutral	—	$9.63	$8.98	-6.7%	-13.9%	-3.9%	-5.0%	-6.4%	-5.4%
May 8	Raymond James	Maintains	Strong Buy → Strong Buy	—	$23.61	$22.73	-3.7%	-10.2%	-15.4%	-13.4%	-15.8%	-17.5%
Mar 4	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$15.83	$14.90	-5.9%	+7.5%	+11.7%	+6.8%	+7.5%	+4.9%
Nov 8	Raymond James	Maintains	Strong Buy → Strong Buy	—	$19.72	$20.76	+5.3%	+14.7%	+14.0%	+10.4%	+8.9%	+2.4%
Nov 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$19.72	$20.76	+5.3%	+14.7%	+14.0%	+10.4%	+8.9%	+2.4%
Oct 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$17.15	$17.03	-0.7%	-4.5%	-3.3%	-4.1%	-6.0%	-8.0%
Sep 20	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$19.74	$19.87	+0.7%	+1.2%	+1.5%	-2.3%	-1.3%	-1.5%
Aug 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$15.96	$16.02	+0.4%	+3.1%	+8.2%	+10.1%	+10.2%	+10.0%
Aug 9	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$12.19	$15.10	+23.9%	+30.9%	+34.9%	+41.7%	+44.1%	+44.3%
Jul 9	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$11.64	$11.81	+1.5%	+2.7%	+3.1%	+5.8%	+9.8%	+15.0%
Jun 20	Mizuho	Maintains	Buy → Buy	—	$10.62	$10.82	+1.9%	+0.8%	+3.6%	+3.7%	+3.7%	+2.1%
May 10	Mizuho	Maintains	Buy → Buy	—	$6.93	$8.20	+18.3%	+27.1%	+26.8%	+32.2%	+31.3%	+30.7%
May 10	Raymond James	Maintains	Strong Buy → Strong Buy	—	$6.93	$8.20	+18.3%	+27.1%	+26.8%	+32.2%	+31.3%	+30.7%
May 10	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$6.93	$8.20	+18.3%	+27.1%	+26.8%	+32.2%	+31.3%	+30.7%
May 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.93	$8.20	+18.3%	+27.1%	+26.8%	+32.2%	+31.3%	+30.7%
Mar 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.39	$6.49	+1.6%	+1.7%	+5.5%	+3.3%	+2.3%	+0.8%
Mar 1	Mizuho	Maintains	Buy → Buy	—	$5.36	$5.38	+0.4%	+3.0%	+6.7%	+8.2%	+14.2%	+14.9%
Feb 29	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$5.38	$5.38	+0.0%	-0.4%	+2.6%	+6.3%	+7.8%	+13.8%
Feb 29	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.38	$5.38	+0.0%	-0.4%	+2.6%	+6.3%	+7.8%	+13.8%
Jan 22	Mizuho	Maintains	Buy → Buy	—	$5.01	$5.00	-0.2%	+5.6%	+5.2%	+0.8%	+1.4%	+1.6%
Jan 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.81	$4.79	-0.4%	+5.4%	+3.1%	+2.7%	+3.7%	+2.5%
Dec 19	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$4.14	$4.19	+1.2%	+1.9%	-1.2%	-0.2%	+2.4%	+5.3%
Nov 17	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.81	$3.84	+0.8%	+4.2%	+5.8%	+3.4%	+3.7%	+3.9%
Aug 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$4.06	$4.20	+3.4%	+6.2%	+10.3%	+13.5%	+11.8%	+9.4%
Aug 10	Raymond James	Maintains	Strong Buy → Strong Buy	—	$4.06	$4.20	+3.4%	+6.2%	+10.3%	+13.5%	+11.8%	+9.4%
Aug 10	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$4.06	$4.20	+3.4%	+6.2%	+10.3%	+13.5%	+11.8%	+9.4%
Mar 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.32	$3.37	+1.5%	+0.0%	-3.3%	-1.5%	-4.8%	-0.3%
Feb 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.86	$3.89	+0.8%	-1.8%	-6.7%	-7.3%	-5.2%	-7.0%
Jan 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.88	$3.94	+1.5%	-0.3%	-5.9%	-7.2%	-6.4%	-9.5%
Nov 10	Mizuho	Maintains	Buy → Buy	—	$2.47	$2.77	+12.1%	+27.5%	+32.4%	+34.0%	+31.2%	+27.9%
Oct 13	Mizuho	Maintains	Buy → Buy	—	$2.54	$2.55	+0.4%	+6.3%	+3.1%	+5.9%	+7.9%	+2.0%
Jul 25	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.17	$2.16	-0.5%	+0.9%	-1.8%	-0.5%	+0.0%	-1.4%
Nov 11	Raymond James	Upgrade	Outperform → Strong Buy	—	$1.40	$1.51	+7.9%	+13.6%	+18.6%	+10.7%	+10.7%	+7.1%
Nov 9	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$1.38	$1.45	+5.1%	+2.9%	+1.4%	+15.2%	+20.3%	+12.3%
Oct 26	Raymond James	Maintains	Outperform → Outperform	—	$1.23	$1.26	+2.4%	+9.8%	+9.8%	+8.9%	+4.9%	+9.8%
Aug 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.53	$1.55	+1.3%	-1.3%	-2.6%	-5.9%	-13.1%	-16.3%
Jul 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.55	$1.57	+1.3%	-2.6%	-4.5%	-7.7%	-3.2%	-7.1%
Mar 26	Raymond James	Maintains	Outperform → Outperform	—	$2.05	$1.96	-4.4%	-11.7%	-18.5%	-16.6%	-14.1%	-10.7%
Jan 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.95	$2.02	+3.6%	+8.2%	+10.3%	+6.7%	+10.3%	+9.7%
Oct 1	Raymond James	Maintains	Outperform → Outperform	—	$2.39	$2.41	+0.8%	-6.7%	+4.2%	+4.2%	+1.3%	+7.1%
May 7	Oppenheimer	Maintains	Outperform → Outperform	—	$3.20	$2.90	-9.4%	-18.1%	-24.4%	-16.6%	-20.3%	-22.2%
Mar 16	H.C. Wainwright	Maintains	Buy → Buy	—	$2.16	$1.84	-14.8%	-16.7%	-7.4%	-30.6%	-2.3%	+4.2%
Mar 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.16	$1.84	-14.8%	-16.7%	-7.4%	-30.6%	-2.3%	+4.2%
Jun 4	Jefferies	Maintains	Buy → Buy	—	$4.20	$4.31	+2.6%	+4.5%	+2.6%	-10.2%	-10.0%	-10.2%
Apr 2	Oppenheimer	Maintains	Outperform → Outperform	—	$4.07	$6.26	+53.8%	+24.3%	+25.8%	+27.5%	+24.8%	+26.3%
Oct 30	H.C. Wainwright	Maintains	Buy → Buy	—	$5.03	$5.30	+5.4%	+6.6%	+6.8%	+9.9%	+11.7%	+11.3%
Oct 12	Raymond James	Maintains	Outperform → Outperform	—	$5.56	$5.58	+0.4%	-5.9%	-3.6%	-4.9%	-3.4%	+0.4%
Jul 30	Chardan Capital	Maintains	Buy → Buy	—	$6.09	$6.58	+8.0%	+3.1%	+7.1%	+5.1%	+2.6%	+2.3%

Recent Filings

8-K · 8.01 !! High

ADMA Biologics, Inc. -- 8-K 8.01: Material Event / Announcement

ADMA Biologics received FDA approval to expand ASCENIV's label to pediatric immunocompromised patients aged 2+, potentially broadening its addressable market and revenue opportunities.

May 4

8-K · 7.01 ! Medium

Unknown — 8-K 7.01: Regulation FD Disclosure

ADMA disclosed material information via Regulation FD, suggesting the company made a public announcement; investors should monitor the complete filing details to assess implications for operations, financial performance, or strategic direction.

Mar 27

8-K · 8.01 !! High

ADMA Biologics, Inc. -- 8-K 8.01: Material Event / Announcement

ADMA Biologics disclosed a material announcement in its press release, though the specific details require review of the exhibit for investor impact assessment.

Mar 2

8-K · 5.02 !!! Very High

ADMA Biologics, Inc. -- 8-K 5.02: Executive Change

ADMA Biologics appointed Mr. Kohler as Chief Financial Officer while director Tade resigned, signaling potential operational restructuring that investors should monitor for impact on financial management and governance.

Feb 25

Data updated apr 24, 2026 10:57am · Source: massive.com